On August 18, 2026, women's telehealth platform Midi Health unveiled a new brand identity as it expands beyond menopause care into a broader set of women's health services. The refresh follows a $100 million round earlier this year at a $1 billion valuation and arrives with more than 450,000 patients served, according to the company.

Why It Matters

Menopause was the femtech category everyone piled into; it is now the category everyone is trying to graduate from. The economics are unforgiving — as the shutdown of perimenopause platform Play Health demonstrated just last week, a single-symptom, cash-pay wedge struggles to find reimbursement because payers keep treating better menopause care as a "nice to have." Midi's answer is to widen the clinical aperture until it looks like longitudinal primary care for women, where lifetime value and payer relationships actually pencil out. That makes this a bellwether. Midi is the best-capitalized company in the space, and its pivot from specialist to generalist tells every seed-stage menopause startup what the endgame looks like: either become a durable longitudinal platform or become an acquisition. It also puts Midi on a collision course with Hers, Maven and the broader women's telehealth field rather than the narrow menopause cohort it used to sit in. For the sexual wellness side of the house, the relevant detail is that vaginal estrogen, hormone therapy and libido-adjacent care are now bundled inside a mainstream, insurance-oriented clinical platform serving nearly half a million patients. That's a quieter but more consequential form of destigmatization than any marketing campaign — sexual health arriving as a line item on a care plan next to thyroid panels.

The strategic move is bigger than the logo. Midi is adding clinical pathways beyond midlife — including metabolic health and PCOS support — and consolidating labs, hormone therapy and supplements into a single platform experience. The company says its AI-powered clinical tools help providers deliver personalized, evidence-based care while keeping clinical judgment and empathy at the center. Its own site now frames care plans around symptom-first language spanning hormone testing, HRT patches, vaginal estrogen, GLP-1s, thyroid and metabolic labs, and bone density screening.

"We are laying the foundation for Midi's next era of growth," said CEO and co-founder Joanna Strober. "As the lines between primary and specialty care begin to converge, we are perfectly positioned to take on both the specialized and primary care needs of our patients. We've earned women's trust by delivering compassionate, effective, clinician-led care through midlife, and we're now applying that same model to more and new clinical care types." Chief Marketing Officer Melissa Waters added that patients want "a highly personalized, trusted healthcare partner not just at one moment in their lives, but across every stage."

The visual work is a deliberate departure from the soft, muted palette that has been women's-health design shorthand for a decade, leaning instead on bold typography and high-contrast color to signal a broader ambition.

Sources

Update — 2026-08-19

Initial entry — story first created.